Skin Cancer and Melanoma Market Research
Delivered September 24, 2019. Contributor: Arwen
Determine the competitive landscape of the skin cancer and melanoma market. The information will be used to steer the direction of a company and to raise funding.
SKIN CANCER AND MELANOMA MARKET SIZE AND GROWTH
The global skin cancer therapeutics market is seen to grow at a rate of
10.4% from 2019 to 2024
The growth of this market is propelled by the
rise in skin cancer prevalence
, expansion in R&D initiatives, and increased awareness about the disease.
As for the melanoma therapeutics market size, its value is
$4.2 billion in 2016
and is expected to increase by
11.21% from 2018 to 2025
reverse CAGR calculator
, the market size forecast of the melanoma therapeutics segment was derived to be
$5.78 billion in 201
Based on the evaluation of the American Academy of Dermatology,
is the most prevalent type of cancer in the United States.
The majority of melanoma cases occurred due to
UV light exposure
Globally, the major players in the market include
Amgen, Inc., the Bristol-Myers Squibb Company
, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., and others.
startups in the skin cancer and melanoma sector include
, DermTech, Skin Vision, and others.
20 times more prevalent
in Caucasians compared to Blacks.
Overall, the lifetime incidence rates of acquiring the disease is "
2.5% (1 in 40)
0.1% (1 in 1,000)
for blacks, and
0.5% (1 in 200)
are anticipated to have a melanoma diagnosis in 2019.
The condition is also the most prevalent cancer type among the
25 to 29-year-old age
group in the United States.
For those who are in the
15 to 29 age group
, the disease is the "
3rd most common for men
and the 4th most common for women."
The average age of those who will have this disease is
are seen to expire from the disease in 2019.
Of this number,
are men and
MELANOMA DIAGNOSTIC TOOLS
Some of the latest tools to detect melanoma include the use of "
multispectral digital skin lesion analysis (MDSLA)
This method utilizes "
10 spectral wavelengths
to measure the light reflected from the tissue" to generate a risk score.
This device helped in improving the "biopsy sensitivity for melanoma from
65% to 93% among 179
dermatologists who reviewed images of
24 lesions, 5
of which were melanoma."
In other regions, the
"spectrophotometric intracutaneous analysis scope
" is used to diagnose the condition.
It uses the
same analytic technique
as the MDSLA device.
The latest study on this tool revealed a good sensitivity level of
and a specificity of
Only the project owner can select the next research path.
Need a similar proposal?
Let's launch your next project!